Fresenius Medical Care AG (NYSE:FMS)‘s stock had its “hold” rating reiterated by HSBC in a research note issued on Tuesday.

FMS has been the topic of several other research reports. DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG in a research report on Thursday, August 4th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, September 13th. Citigroup Inc. reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday. SunTrust Banks Inc. set a $48.00 price target on Fresenius Medical Care AG and gave the stock a “buy” rating in a research report on Thursday, October 13th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $44.33.

Analyst Recommendations for Fresenius Medical Care AG (NYSE:FMS)

Shares of Fresenius Medical Care AG (NYSE:FMS) traded up 0.60% on Tuesday, hitting $42.03. The stock had a trading volume of 88,289 shares. The firm has a 50 day moving average of $43.52 and a 200 day moving average of $43.77. The stock has a market cap of $25.70 billion, a P/E ratio of 23.30 and a beta of 0.58. Fresenius Medical Care AG has a 12 month low of $38.71 and a 12 month high of $47.52.

Fresenius Medical Care AG (NYSE:FMS) last issued its earnings results on Tuesday, August 2nd. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.04. Fresenius Medical Care AG had a return on equity of 9.66% and a net margin of 6.40%. The business had revenue of $4.42 billion for the quarter, compared to analyst estimates of $4.54 billion. On average, equities analysts forecast that Fresenius Medical Care AG will post $2.01 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of FMS. Quadrant Capital Group LLC increased its stake in Fresenius Medical Care AG by 0.9% in the second quarter. Quadrant Capital Group LLC now owns 2,789 shares of the company’s stock worth $114,000 after buying an additional 24 shares during the period. Checchi Capital Advisers LLC increased its stake in Fresenius Medical Care AG by 5.5% in the second quarter. Checchi Capital Advisers LLC now owns 3,449 shares of the company’s stock worth $150,000 after buying an additional 179 shares during the period. Rothschild Investment Corp IL acquired a new stake in Fresenius Medical Care AG during the third quarter worth $222,000. Atria Investments LLC acquired a new stake in Fresenius Medical Care AG during the third quarter worth $234,000. Finally, Sterling Capital Management LLC acquired a new stake in Fresenius Medical Care AG during the second quarter worth $235,000. Hedge funds and other institutional investors own 2.49% of the company’s stock.

About Fresenius Medical Care AG

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Stock Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related stocks with our FREE daily email newsletter.